Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.
Metrion Biosciences looks to partner and move its lead candidate into clinical trials later this year fueled by a funding round which will also see its drug discovery services expand throughout 2019.
Sutro Biopharma and Merck have signed a collaboration and licensing agreement, which will leverage Sutro's proprietary cell-free protein synthesis and site-specific conjugation platforms.